Diagnocure, Inc.
Other OTCTotal Valuation
Diagnocure, Inc. carries a market capitalization of 21,520.00, placing it among publicly traded companies globally. Its enterprise value stands at -246,662.15, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21,520.00 |
| Enterprise Value | -246,662.15 |
Share Statistics
Diagnocure, Inc. currently has 43.04M shares outstanding.
| Shares Outstanding | 43.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Diagnocure, Inc. trades at a trailing price-to-earnings ratio of 0.05. The price-to-sales ratio is 0.02, and the price-to-book ratio stands at 0.00.
| PE Ratio | 0.05 |
| PS Ratio | 0.02 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | -0.14 |
| P/OCF Ratio | -0.13 |
Enterprise Valuation
The EV/Sales ratio of 30.24 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 0.15 provides insight into valuation relative to core operating earnings.
| EV / Sales | 30.24 |
| EV / EBITDA | 0.13 |
| EV / EBIT | 0.15 |
| EV / FCF | N/A |
Financial Position
Diagnocure, Inc. maintains a current ratio of 3.74, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.74 |
| Quick Ratio | 3.45 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 2,806.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 114.36 |
| Return on Invested Capital (ROIC) | 126.55 |
| Return on Capital Employed (ROCE) | -5.24 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Diagnocure, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Diagnocure, Inc. generated 6.68M in revenue and converted that into 2.74M in net income, yielding earnings per share of 0.06. EBITDA reached 3.13M, while operating income came in at 2.73M.
| Revenue | 6.68M |
| Gross Profit | 243,834.00 |
| Operating Income | 2.73M |
| Pretax Income | 2.74M |
| Net Income | 2.74M |
| EBITDA | 3.13M |
| EBIT | 2.73M |
| Earnings Per Share (EPS) | 0.06 |
Balance Sheet
Total book value stands at -99.91M, with working capital of 368,921.00 providing operational flexibility.
| Cash & Cash Equivalents | 392,486.00 |
| Total Debt | N/A |
| Net Debt | -392,486.00 |
| Equity (Book Value) | -99.91M |
| Book Value Per Share | -2.32 |
| Working Capital | 368,921.00 |
Cash Flow
Diagnocure, Inc. produced -1.08M in operating cash flow over the past twelve months. After subtracting -10,642.00 in capital expenditures, free cash flow totaled -1.09M - equivalent to -0.03 per share.
| Operating Cash Flow | -1.08M |
| Capital Expenditures | -10,642.00 |
| Free Cash Flow | -1.09M |
| FCF Per Share | -0.03 |
Margins
Diagnocure, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 40.87 and net profit margin of 41.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | 40.87 |
| Pretax Margin | 41.00 |
| Profit Margin | 41.00 |
| EBITDA Margin | 46.87 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 19.04 |
| FCF Yield | -734.89 |
Scores
Diagnocure, Inc. posts an Altman Z-Score of -245.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -245.06 |